Dianthus Therapeutics Inc. (DNTH NASDAQ) stock market data APIs
$37.2073
0.47(1.3%)
as of September 15, 2025
Try our APIs with
free plan!
Dianthus Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prev. Close
37.2073
Open
37.6723
High
37.6368
Low
36.1846
52 wk Range
13.365-38.59
Market Cap
1 480 M
Shares Outstanding
39 816 K
Revenue
4 854 K
EPS
-0.88
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Dianthus Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dianthus Therapeutics Inc. data using free add-ons & libraries
Get Dianthus Therapeutics Inc. Fundamental Data
Dianthus Therapeutics Inc. Fundamental data includes:
- Net Revenue: 4 854 K
- EBITDA: -129 812 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dianthus Therapeutics Inc. News
New
Implied XBI Analyst Target Price: $142
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, an...
Notable Friday Option Activity: GLW, DNTH, CROX
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Corning Inc (Symbol: GLW), where a total volume of 46,563 contracts has been trade...
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antib...
Dianthus Therapeutics prices upsized $251M securities offering
Dianthus Therapeutics (NASDAQ:DNTH [https://seekingalpha.com/symbol/DNTH]) has priced [https://seekingalpha.com/pr/20227263-dianthus-therapeutics-inc-announces-pricing-of-upsized-251-million-underwrit...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
